Alphatec (Carlsbad, Calif.)

After making leadership changes this year, Alphatec expects to see around $101.4 million in full-year 2017 revenue, with U.S. commercial revenue hitting $86.8 million to $87 million. In the fourth quarter of 2017 alone, Alphatec predicts revenue to hit $25.9 million to $26.3. Alphatec ended 2017 with a cash balance of $22.5 million. The increase in revenue follows the appointment of former NuVasive executive as its new executive chairman. Along with making changes internally, Alphatec launched its Battalion Lateral System with the Alphatec Squadron Lateral Rector for minimally invasive lateral access procedures.

Arthrex (Naples, Fla.)

To keep with its growing 11,000 products for arthroscopic and minimally invasive orthopedic procedures, Arthtrex is starting 2018 with construction on a $30 million manufacturing plant in Anderson County, S.C. The company’s physical expansion doesn’t stop with a manufacturing plant; this year Arthrex set out to expand its headquarters, building a $73 million administrative and event office for visiting surgeons. The headquarter expansion should add more that 500 employees to Arthrex’s team. Its rapid expansion solidified Arthrex to continue its partnership with NBC Sports.

Camber Spine (Wayne, Pa.)

Camber Spine started 2017 on a strong foot. The company earned FDA clearance for its Siconus SI Joint Fixation System, Camber Spine’s second product for sacroiliac disease treatment. Similar with how Camber Spine started 2017, the company ended the year receiving FDA clearance for the SPIRA-C Open Matrix Cervical Interbody device. The company launched its other SPIRA products, SPIRA Open Matrix ALIF in 2017, and surgeons implanted more than 150 ENZA Zero-Profile ALIF devices throughout the year.

DePuy Synthes (Warsaw, Ind.)

With spine on its mind, DePuy Synthes spent 2017 making strategic developments and relationships for further business growth. The Johnson & Johnson subsidiary acquired Innovative Surgical Solutions, known commonly as Sentio, a nerve localization technology company, to strengthen its spine segment. Additionally, DePuy Synthes launch its Viper Prime spine system, a minimally invasive pedicle screw system designed for fusion procedures. To establish itself as a minimally invasive techniques developer, DePuy Synthes also unveiled its Purevue Visualization System for endoscopic surgery. The company’s plans to expand its spine business do not have an end in sight.

Exactech (Gainesville, Fla.)

In December 2017, Exactech merged with TPG Capital in a $737 million deal, up 17.3 percent from TPG’s original bid to acquire Exactech. The increase in the acquisition cost is due to Exactech’s rising revenue and recent device launches. Exactech’s third quarter 2017 revenues jumped 2 percent to $61.4 million compared to the third quarter of 2016. The company’s extremities segment saw the largest surge in revenues, increasing 18 percent to $27.7 million. To compete with other robotics developers, Exatech launched a new computer-assisted software for total knee replacement, the Exactech GPS TKA Plus in conjunction with the company’s Truliant Knee System.

Globus Medical (Audubon, Pa.)

FDA approvals, acquisitions and rising revenue-filled Globus Medical’s calendar in 2017. One of the company’s highlights included receiving FDA clearance for its Excelsius GPS, a robotic guidance and navigation system. Globus Medical also acquired KB Medical, a robotic developer, to further its position in robotic spine and orthopedic surgery. Noting its growth as 100 percent organic, Globus Medical saw a 12.7 percent increase in 2017 full year sales totaling $635.4 million. In 2018, the company has big plans to blossom with plans to generate $690 million in sales.

Implanet (Bordeaux, France)

Jazz isn’t just music to Implanet. The medical device developer spent 2017 expanding its Jazz brand starting with earning the CE Mark for its Jazz Passer. Implanet’s Jazz Passer is designed for posterior fixation in spine surgery. After filing for various Jazz patents in 2017, Implanet ended the year with 22 patents. All of these new developments lead Implant to see 20 percent revenue growth in the third quarter. The company’s Jazz spinal implant sales grew 30 percent in the quarter and were up 23 percent for the year. Last reported in September 2017, Implanet sold 6,296 Jazz implants.